Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

US clinical-stage oncology focused biotech Celcuity saw its shares skyrocket 180% to $38.59 in early trading as it announced ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity said its Phase 3 clinical trial evaluating gedatolisib resulted in positive topline results. The clinical-stage biotechnology company's trial evaluated gedatolisib plus fulvestrant with and ...

PATIENTS AND METHODS: Patients (n = 451) with advanced breast cancer were randomized to receive fulvestrant 250 mg as a once-monthly (one × 5 mL) intramuscular injection or an oral dose of anastrozole ...